RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer.
Kazuhiko NakagawaErnest NadalEdward B GaronMakoto NishioTakashi SetoNobuyuki YamamotoKeunchil ParkJin-Yuan ShihLuis Paz-AresBente Frimodt-MollerAnnamaria H ZimmermannSameera WijayawardanaCarla Visseren-GrulMartin Recknull nullPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
RAM+ERL provided significant clinical benefit for both EGFR ex19del and ex21L858R NSCLC, supporting this regimen as suitable for patients with either of these EGFR mutation types.